Topics
Medulloblastoma | Outcomes | Milano-HART strategy
Home > Publications > Topics > Medulloblastoma > Outcomes > Milano-HART strategy
*Massimino M, Barretta F, Dossena C, Minasi S, Buttarelli FR,
Biassoni V, Oriani M, Schiavello E, Ficorilli M, Nigro O, Pollo B,
Antonelli M, Donofrio V, Maggioni M, Kool M, Pecori E, Vennarini
S, Giangaspero F, Gianno F, Erbetta A, Chiapparini L, Luksch R,
Barzanò E, Meazza C, Podda M, Spreafico F, Terenziani M,
Bergamaschi L, Ferrari A, Casanova M, Chiaravalli S, Gattuso G,
Modena P, Bailey S, De Cecco L.
Long-term
outcome of the Milano-HART strategy for high-risk medulloblastoma,
including the impact of molecular subtype.
Neuro
Oncol. 2024 Sep 27:noae189. doi:
10.1093/neuonc/noae189. PMID:
39331528. Observational study. ˍ
Gottardo NG, Gajjar A.
Determining
Risk Features for Medulloblastoma in the
Molecular Era.
Neuro
Oncol. 2024 Oct 25:noae223. doi:
10.1093/neuonc/noae223. PMID:
39450440. Comment. ˍ
Refers
to:
*Massimino M, Barretta F, Dossena C, Minasi S, Buttarelli
FR, Biassoni V, Oriani M, Schiavello E, Ficorilli M, Nigro O,
Pollo B, Antonelli M, Donofrio V, Maggioni M, Kool M, Pecori E,
Vennarini S, Giangaspero F, Gianno F, Erbetta A, Chiapparini L,
Luksch R, Barzanò E, Meazza C, Podda M, Spreafico F,
Terenziani M, Bergamaschi L, Ferrari A, Casanova M, Chiaravalli S,
Gattuso G, Modena P, Bailey S, De Cecco L.
Long-term
outcome of the Milano-HART strategy for high-risk medulloblastoma,
including the impact of molecular subtype.
Neuro
Oncol.
2024 Sep 27:noae189. doi:
10.1093/neuonc/noae189. PMID:
39331528. Observational study. ˍ